SHASUNPHAR

Taru Mayur has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Usha Abhaykumar has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

S. Abhayakumar has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of letter from Company's Managing Director dated November 05, 2011 to be sent to the Company's Shareholders.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on October 07, 2011 have considered the allotment of Convertible Warrants on Preferential basis to the Promoters & Directors of the Company.

Shasun Pharmaceuticals Limited had informed the Exchange regarding the dispatch of Notice pursuant Section 192A of the Companies Act, 1956 containing special resolution relating to issue and allot upto 15,00,000 convertible warrants to the Promoters and Directors of the company on Preferential basis. The Company has now informed the Exchange that as per the report dated September 30, 2011 submitted by Mr. S. Dhanapal, Practicing Company Secretary appointed as Scrutinizer for conducting the process of voting by Postal Ballot, the above mentioned Resolution in the said Notice have been approved

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of Notice of Postal Ballot pursuant to Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange regarding the following changes in the Board of Directors of the Company with effective from August 19, 2011 : (1) Mr. Tapan Ray, Independent Director & Mr. V F Banaji, Independent Director have resigned.; (2) Mr. N. Subramanian is inducted as Independent Director; (3) Mr. M Mohan is inducted as Wholetime Director. The changes have been recorded and approved at the Board of Directors' Meeting held on August 19, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 19, 2011 decided to issue and allot 15,00,000 warrants on preferential basis to promoters / promoter Group(s) and Directors with each warrant convertible into one equity share of the company as per the SEBI Guidelines and subject to the approval of the Share holders. The Board has decided to obtain Shareholders approval by way of Postal Ballot.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on July 29, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors at their meeting held on May 30,2011 have decided to close the Share Transfer Books of the Company during the period from July 22, 2011 to July 29, 2011 (both days inclusive) for the purpose of the dividend & AGM to be held on July 29,2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2011 has recommended a dividend of 15% (Rs.0.30 per share) on the equity share of Rs.2/- each, subject to shareholder approval at the ensuing Annual General Meeting.

Shasun Pharmaceuticals Limited has informed the Exchange regarding the following changes in the Board of Directors of the Company : Mr. A. Mahendran has resigned from the Directorship of the Company and Mr. R Sundara Rajan is appointed as Director with effect from May 30, 2011. The changes have been recorded and approved at the Board of Directors' Meeting held on May 30, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Shasun Pharmaceuticals Limited has informed the Exchange that an amicable settlement has been reached with the workers at the Company's Pondicherry API Unit. The strike has been called off and operations resumed from May 25, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that "An illegal strike was resorted by the workers at our Pondicherry API Unit on 10th May 2011. The Company is doing needful to resume the operations at the earliest".

Citibank N.A. has submitted to the Exchange a copy of disclosure under regulations 7(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Citibank N.A. has submitted to the Exchange a copy of disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Shasun Pharmaceuticals Limited has informed the Exchange that the company will be publishing Audited Results, for the financial year 2010-11, within sixty days and therefore unaudited results for the quarter ending March 31, 2011 will not be published by the company.

Shasun Pharmaceuticals Limited has informed the Exchange that the Company has been permitted to resume the operations at Cuddalore factory on April 22, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that Mr. S. Muralikrishna has been appointed as Company Secretary w.e.f. from April 20, 2011 and he will be the Compliance Officer of the company.

Shasun Pharmaceuticals Limited has informed the Exchange vide its letter dated April 22, 2011, that "The Company has been permitted to resume the operations at our Cuddalore factory today".

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of the Minutes of the proceedings at the Extraordinary General Meeting of the Company held on March 24, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that there was chemical leak in the stores area at their Cuddalore factory on March 7, 2011 night which has been controlled. The production in the factory has been stopped on the direction of the government authorities. The Company is doing the needful to resume the operations at the earliest.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of the notice of the Extraordinary General Meeting of the members of the Company to be held on March 24, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that Mr. Somnath Iyer, Chief Financial Officer has resigned from the services of the company. Mr. S. Hariharan will be the new Chief Financial Officer cum Compliance Officer of the company with immediate effect.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors, at their meeting held on January 28, 2011 has recommended the appointment of M/s. B S R & Co., Chartered Accountants having the firm registration no.101248W allotted by the Institute of Chartered Accountants of India (ICAI) as statutory auditors of the Company to fill the casual vacancy of auditor due to resignation of existing statutory auditors M/s.V.Jagadisan & Co, Chartered Accountants in the ensuing Extra Ordinary General Meeting of the Company to hold office until the conclusion of the next annual gener

Shasun Pharmaceuticals Limited has informed the Exchange vide its letter dated February 11, 2011 that Mr. Somnath Iyer, Chief Financial officer cum Compliance Officer has resigned from the services of the company. Mr. S. Hariharan will be the new Chief Financial Officer cum Compliance Officer of the company with immediate effect.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2010.

Members of the Exchange are hereby informed that the name of Shasun Chemicals and Drugs Limited shall be changed to Shasun Pharmaceuticals Limited and the trading symbol of the Company be changed from SHASUNCHEM to SHASUNPHAR w.e.f. January 28, 2011.

Shasun Chemicals And Drugs Limited has informed the Exchange vide its letter dated November 08, 2010, that "Mr.Dinesh Bhutda, Company Secretary cum Compliance Officer has resigned from the services of the Company. Mr.Somnath Iyer, Chief Financial Officer will be the new Compliance Officer of the company with immediate effect".

Shasun Chemicals and Drugs Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2010.

Shasun Chemicals And Drugs Limited has informed the Exchange regarding a press release dated August 27, 2010, titled "Shasun embarks into Nanotech: Announces collaboration with NBI".

Shasun Chemicals And Drugs Limited has informed the Exchange regarding Minutes of proceedings of the Annual General Meeting of the Company held on July 30, 2010.

Shasun Chemicals And Drugs Limited has informed the Exchange that the name of the Company has been changed to "Shasun Pharmaceuticals Limited" from "Shasun Chemicals And Drugs Limited".

Shasun Chemicals And Drugs Limited has informed the Exchange that the Board of Directors at its meeting held on July 30, 2010, allotted 39,300 fully paid equity share of Rs.2/- each under ESOP - 2001 to employees of the Company.

Shasun Chemicals And Drugs Limited has informed the Exchange that "Mr. N. Govindarajan, CEO and MD has resigned. Mr. S. Vimal Kumar, whole time director has been appointed as Managing Director, effective July 30, 2010".

Shasun Chemicals And Drugs Limited has informed the Exchange that the Annual General Meeting of the Company will be held on July 30, 2010. Further the Registrar of Members and Share Transfer Books will remain closed from July 27, 2010 to July 30, 2010 (both days inclusive) for the purpose of Annual General Meeting and for determining the shareholders who are eligible for dividend, if declared at AGM.

Shasun Chemicals And Drugs Limited has informed the Exchange that the Company has allotted 1,91,666 fully paid equity shares of Rs.2/- each under Shasun ESOP 2006 to employees of its subsidiary Company.

Shasun Chemicals And Drugs Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2010 has recommended a Dividend of 50% (Rs. 1 per share) on the equity shares of face value of Rs. 2/- each, subject to shareholders approval at ensuing Annual General Meeting.

Shasun Chemicals And Drugs Limited has informed the Exchange that the registered & corporate office of the company has been shifted to the following address with effect from April 26, 2010 :- "Shasun Chemicals And Drugs Limited, 'Batra Centre', 28, Sardar Patel Road, 3rd and 4th floor, Guindy, Chennai 600032, Tamil Nadu, India".

Shasun Chemicals And Drugs Ltd. has informed the Exchange that:"Shasun Chemicals And Drugs Limited regrets to announce the sad demise of its independent director and Chairman of Audit Committee, Mr. S.Krishnan. Mr. S. Krishnan passed away unexpectedly on Sunday, February 28, 2010 at the age of 67. The Company offers its heart felt condolences to Krishnan's family".

Shasun Chemicals And Drugs Ltd. has informed the Exchange vide its letter dated September 11, 2009 that "Tamil Nadu Pollution Control Board (TNPCB) has revoked its closure notice of the Cuddalore plant situated at SIPCOT Industrial complex in Cuddalore, Tamil Nadu. The Cuddalore unit is restarting its operations today".

Shasun Chemicals And Drugs Ltd. has informed the Exchange that: "The sale of Annan plant at Scotland belonging to our step-down subsidiary, Shasun Pharma Solutions Limited, which was closed in March 2009 has been successfully concluded. The plant has been sold to Phoenix Chemicals, Wirral, Cheshire, England".

Shasun Chemicals And Drugs Ltd. has informed the Exchange that the Board of Directors at their meeting held on July 26, 2009 have decided to close the Share Transfer Books of the Company during September 16, 2009 to September 23, 2009 - both days inclusive for the purpose of AGM to be held on September 23, 2009.

Shasun Chemicals And Drugs Ltd. has informed the Exchange that "Company has received notice from Tamil Nadu Pollution Control Board under The Air (Prevention and Control of Pollution) Act, 1981 for closure of Plant situated at SIPCOT Industrial complex in Cuddalore, Tamil Nadu. Consequent to the notice, the operations at the Cuddalore plant have been stopped effective 25th August 2009. The closure will result in partial disruption to the Cuddalore operations. The Company has preferred an appeal and is confident of resolving the issue at the earliest".

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding the following changes in the Board of the company; Director appointed - Mr. S. Krishnan as additional director w.e.f. July 26, 2009; Director resigned - Mr. C. L. Jain w.e.f. July 27, 2009; Chairman - Mr. A. Mahendran has been appointed as Chairman of the Board of Directors.

Shasun Chemicals And Drugs Ltd. has informed the Exchange regarding the following changes in the Board of the company: 1) Directors Resigned - Mr. D A Prasanna and Dr Jagadish Sheth. 2) Directors appointed in their place - Mr. A Mahendran and Mr. Tapan Ray. The changes have been recorded and approved in the Board of Directors' Meeting held on June 27, 2009.